Literature DB >> 20060451

The role of intermolecular interactions with penetratin and its analogue on the enhancement of absorption of nasal therapeutic peptides.

El-Sayed Khafagy1, Mariko Morishita, Kozo Takayama.   

Abstract

We investigated the relationship between intermolecular binding and the ability of novel cell-penetrating peptides (CPPs) to enhance the nasal absorption of therapeutic peptides and proteins. The absorption-enhancing effect of a novel l-penetratin analogue, 'shuffle (R,K fix) 2' coadministered with different biotherapeutic peptides was evaluated after nasal administration in rats. Shuffle (R,K fix) 2 significantly increased the nasal absorption of insulin, glucagon-like-peptide-1 (GLP-1) and exendin-4, compared with the absorption seen with l-penetratin. Intermolecular binding was analyzed by surface plasmon resonance (SPR)-based binding assay. The binding characteristics implied that the higher the amount of CPP bound, the greater the nasal drug absorption. In addition, the calculated binding ratio between CPP and drug proved a critical aspect in enhancing the absorption of insulin and GLP-1. This difference in the enhancing effect of CPPs on nasal drug absorption is attributed to the degree of binding with the therapeutic macromolecule. Copyright (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20060451     DOI: 10.1016/j.ijpharm.2009.12.060

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  11 in total

1.  Penetratin-Mediated Transepithelial Insulin Permeation: Importance of Cationic Residues and pH for Complexation and Permeation.

Authors:  Mie Kristensen; Henrik Franzyk; Mia Thorne Klausen; Anne Iversen; Jesper Søborg Bahnsen; Rikke Bjerring Skyggebjerg; Vito Foderà; Hanne Mørck Nielsen
Journal:  AAPS J       Date:  2015-05-20       Impact factor: 4.009

Review 2.  Cell-penetrating peptides as tools to enhance non-injectable delivery of biopharmaceuticals.

Authors:  Mie Kristensen; Hanne Mørck Nielsen
Journal:  Tissue Barriers       Date:  2016-04-18

Review 3.  Intranasal glucagon: a promising approach for treatment of severe hypoglycemia.

Authors:  Antonio E Pontiroli
Journal:  J Diabetes Sci Technol       Date:  2014-11-10

Review 4.  Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases.

Authors:  M Elizabeth Meredith; Therese S Salameh; William A Banks
Journal:  AAPS J       Date:  2015-03-24       Impact factor: 4.009

5.  Region-Dependent Role of Cell-Penetrating Peptides in Insulin Absorption Across the Rat Small Intestinal Membrane.

Authors:  El-Sayed Khafagy; Ruisha Iwamae; Noriyasu Kamei; Mariko Takeda-Morishita
Journal:  AAPS J       Date:  2015-07-28       Impact factor: 4.009

6.  Impact Of Penetratin Stereochemistry On The Oral Bioavailability Of Insulin-Loaded Solid Lipid Nanoparticles.

Authors:  Bader B Alsulays; Md Khalid Anwer; Gamal A Soliman; Sultan M Alshehri; El-Sayed Khafagy
Journal:  Int J Nanomedicine       Date:  2019-11-25

7.  Modification of translationally controlled tumor protein-derived protein transduction domain for improved intranasal delivery of insulin.

Authors:  Hae-Duck Bae; Joohyun Lee; Kyu-Yeon Jun; Youngjoo Kwon; Kyunglim Lee
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 8.  A Comprehensive Review of the Evolution of Insulin Development and Its Delivery Method.

Authors:  Vaisnevee Sugumar; Kuan Ping Ang; Ahmed F Alshanon; Gautam Sethi; Phelim Voon Chen Yong; Chung Yeng Looi; Won Fen Wong
Journal:  Pharmaceutics       Date:  2022-07-04       Impact factor: 6.525

9.  Intranasal administration of elastin-like polypeptide for therapeutic delivery to the central nervous system.

Authors:  Jeremy Wd McGowan; Qingmei Shao; Parminder Js Vig; Gene L Bidwell
Journal:  Drug Des Devel Ther       Date:  2016-09-06       Impact factor: 4.162

10.  Modified translationally controlled tumor protein-derived protein transduction domain enhances nasal delivery of exendin-4 as shown with insulin.

Authors:  Hae-Duck Bae; Moonhee Kim; Joohyun Lee; Kyunglim Lee
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.